"Methods And Compositions For Predicting Cancer Survival And Car T Cell Toxicity" in Patent Application Approval Process (USPTO 20240293481).

A patent application from Memorial Sloan-Kettering Cancer Center discusses methods and compositions for predicting cancer survival and CAR T cell toxicity. The application suggests using therapeutic bacteria to determine the likelihood of cancer survival and CAR T cell-associated toxicity in patients receiving CAR T cell therapy. It also describes pharmaceutical compositions containing specific therapeutic bacteria and their spores for treating patients with decreased likelihood of cancer survival and increased likelihood of toxicity. The patent application provides a list of specific bacteria and spores that can be used in these compositions. For more information, please refer to the full patent. [Extracted from the article]